Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia: A case report

Pharmacopsychiatry

Volumn 39, Issue 3, 2006, Pages 115-116

  Roesch Ely, Daniela ^a,c   Gohring K ^a   Gruschka, P ^a   Kaiser, S ^a   Pfuller U ^a   Burlon, M ^b   Weisbrod, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; PERGOLIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; MALE; MOOD; NAUSEA; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEPRESSIVE DISORDER; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FRONTAL LOBE; HALLUCINATIONS; HUMANS; MALE; NEURAL PATHWAYS; PERGOLIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA, PARANOID; SULPIRIDE; TREATMENT OUTCOME;

EID: 33745164613     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-941488     Document Type: Article

References (15)

1. Davis K L, Kahn R S, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486
2. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245-256
3. Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61: 127-132
4. Kampf P, Agelink M W, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38: 39-40
5. Kay S. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989; 7: 59-67
6. Keefe R S, Silva S G, Perkins D O, Lieberman J A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201-222
7. Levi-Minzi S, Bermanzohn P C, Siris S G. Bromocriptine for "Negative Schizophrenia". Compr Psychiatry 1991; 32: 210-216
8. Moller H. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17: 793-823
9. Müller M. Calgary Depressions Rating Skala. 2000 University Mainz,
10. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (Suppl 3): 133-138
11. Ohmori T, Koyama T, Inoue T, Matsubara S, Yamashita I. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol Psychiatry 1993; 33: 687-693
12. Powell J H, al-Adawi S, Morgan J, Greenwood RJ. Motivational deficits after brain injury: effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry 1996; 60: 416-421
13. Sawaguchi T, Goldman-Rakic P S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991 ; 251: 947-950
14. Sekine Y, Takei N, Suzuki K, Nakamura K, Tsuchiya KJ, Takebayashi K, Toulopoulou , Mori N. Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia. J Clin Psychopharmacol 2005; 25: 281-283
15. Simpson G M, Angus J W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19